Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination

BACKGROUND: The Sinovac SARS-CoV-2 inactivated vaccine (CoronaVac) has been demonstrated to be safe, well tolerated, and efficacious in preventing mild and severe Covid-19. Although different studies have demonstrated its short-term immunogenicity, long-term cellular and humoral response evaluations...

Descripción completa

Detalles Bibliográficos
Autores principales: Costa, Priscilla Ramos, Correia, Carolina Argondizo, Marmorato, Mariana Prado, de Carvalho Dias, Juliana Zanatta, Thomazella, Mateus Vailant, da Silva, Amanda Cabral, de Oliveira, Ana Carolina Soares, Gusmão, Arianne Fagotti, Ferrari, Lilian, Freitas, Angela Carvalho, Patiño, Elizabeth González, Grifoni, Alba, Weiskopf, Daniela, Sette, Alessandro, Scharf, Rami, Kallas, Esper Georges, Terrassani Silveira, Cássia Gisele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275662/
https://www.ncbi.nlm.nih.gov/pubmed/35821982
http://dx.doi.org/10.1101/2022.03.16.22272513

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275662/
https://www.ncbi.nlm.nih.gov/pubmed/35821982
http://dx.doi.org/10.1101/2022.03.16.22272513

Ejemplares similares